Get started
Author

Hrishikesh Kulkarni

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 2
Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 1
PA-349 Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light Chain Amyloidosis
2026 · Julia Catini, Ashu Wechalekar, et al. · Clinical Lymphoma Myeloma & Leukemia
Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials
2026 · Xiaowen Wang, Marianna Fontana, et al. · Circulation
POSTER: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
Colonic Complement Factor B Production Is Required To Respond To Tissue Injury 2310076
2026 · Devesha Kulkarni, Aayusha Thapa, et al. · The Journal of Immunology
PDF
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology
Works count: 9
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type